Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Myeloid Leukemia Recurrent: early-phase trial registry
3 of 3 indexed Acute Myeloid Leukemia Recurrent trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Acute Myeloid Leukemia Recurrent: 3 US clinical trials tracked, 3 recruiting.
Acute Myeloid Leukemia Recurrent is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Kura Oncology, running 1 of these trials.
Enrollment posture brief
Registry condition acute-myeloid-leukemia-recurrent
OPEN 3 | RECR 100% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Acute Myeloid Leukemia Recurrent lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Myeloid Leukemia Recurrent on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Myeloid Leukemia Recurrent is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology
NCT05735184
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
University of Maryland, Baltimore
NCT04050280
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
NCT06152809
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Myeloid Leukemia Recurrent records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Myeloid Leukemia Recurrent trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Myeloid Leukemia Recurrent page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Acute Myeloid Leukemia Recurrent trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Kura Oncology sponsors the most Acute Myeloid Leukemia Recurrent trials on record, review their full trial history before evaluating a specific study. See Kura Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Myeloid Leukemia Recurrent condition card totals 3 registered trials; most-linked intervention Venetoclax; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.